Literature DB >> 24482980

Why is premixed insulin the preferred insulin? Novel answers to a decade-old question.

S Kalra1, Y P S Balhara2, B K Sahay3, B Ganapathy4, A K Das5.   

Abstract

A wide range of sources have been used to create an equally wide range of types of insulin (rapid acting, fast acting, premixed, intermediate acting and long acting). While some of these insulins are no longer in clinical use, others are being used extensively across the world. Premixed insulin is the most frequently prescribed and used insulin in Asia; basal insulin is more extensively used in USA. As compared with basal insulin alone, premixed regimens tend to lower HbA1c to a larger degree while providing enhanced convenience. It is a challenge for diabetologists to assess the conflicting guidelines and decide which one to follow. This is especially true with regard to choosing appropriate insulin for initiation of therapy. Besides, ethnicity may play a key role in determining choice of insulin therapy among different populations. Here, the authors discuss the various factors, pharmacological as well as psychological, that have made premixed insulins the preferred insulin for type 2 diabetes in India and the many parts of Asia. The authors utilize well known theories of psychology, namely generalization, cognitive dissonance and concordance to provide a rational explanation for the preference for premixed insulin that Indian people with diabetes, and their physicians, have.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24482980

Source DB:  PubMed          Journal:  J Assoc Physicians India        ISSN: 0004-5772


  11 in total

1.  Solution structure of an ultra-stable single-chain insulin analog connects protein dynamics to a novel mechanism of receptor binding.

Authors:  Michael D Glidden; Yanwu Yang; Nicholas A Smith; Nelson B Phillips; Kelley Carr; Nalinda P Wickramasinghe; Faramarz Ismail-Beigi; Michael C Lawrence; Brian J Smith; Michael A Weiss
Journal:  J Biol Chem       Date:  2017-11-07       Impact factor: 5.157

2.  Understanding Patients' Willingness to Pay for Biphasic Insulin Aspart 30/70 in a Pen Device for Type 2 Diabetes Treatment in an Out-of-Pocket Payment Market.

Authors:  Sreenivasa Murthy; Pankaj Aneja; Arthur Joseph Asirvatham; Lise Lotte N Husemoen; Nicolai A Rhee; Jothydev Kesavadev
Journal:  Pharmacoecon Open       Date:  2021-01-06

3.  Insulin Management of Patients with Inadequately Controlled Type 2 Diabetes Admitted to Hospital: Titration Patterns and Frequency of Hypoglycemia as Results of a Prospective Observational Study (Hospital Study).

Authors:  Jan Brož; Denisa Janíčková Žďárská; Jana Urbanová; Pavlína Piťhová; Viera Doničová; Sabina Pálová; Barbora Pelechová; Anna Smržová; Milan Kvapil
Journal:  Diabetes Ther       Date:  2021-05-24       Impact factor: 2.945

Review 4.  Review of insulin-associated hypoglycemia and its impact on the management of diabetes in Southeast Asian countries.

Authors:  Su-Yen Goh; Zanariah Hussein; Achmad Rudijanto
Journal:  J Diabetes Investig       Date:  2017-05-04       Impact factor: 4.232

5.  An Audit of Insulin Usage and Insulin Injection Practices in a Large Indian Cohort.

Authors:  Manash P Baruah; Sanjay Kalra; Saptarshi Bose; Jumi Deka
Journal:  Indian J Endocrinol Metab       Date:  2017 May-Jun

6.  Choice of Insulin in Type 2 Diabetes: A Southeast Asian Perspective.

Authors:  Sanjay Kalra; Hong Quang Thai; Chaicharn Deerochanawong; Goh Su-Yen; Mafauzy Mohamed; Tint Swe Latt; Than Than Aye; Zafar Ahmed Latif; Prasad Katulanda; Touch Khun; Sum Satha; Vadsana Vongvandy
Journal:  Indian J Endocrinol Metab       Date:  2017 May-Jun

7.  Comparison of the Effect of Glycemic Control in Type 2 Diabetes Outpatients Treated With Premixed and Basal Insulin Monotherapy in China.

Authors:  Guangxu Liu; Jingtao Dou; Yuesong Pan; Yuxiang Yan; Huiping Zhu; Juming Lu; Herbert Gaisano; Linong Ji; Yan He
Journal:  Front Endocrinol (Lausanne)       Date:  2018-10-29       Impact factor: 5.555

8.  The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin.

Authors:  Florence Hui Sieng Tan; Chin Voon Tong; Xun Ting Tiong; Bik Kui Lau; Yueh Chien Kuan; Huai Heng Loh; Saravanan A/L Vengadesa Pillai
Journal:  J ASEAN Fed Endocr Soc       Date:  2021-09-03

9.  Comparison of Basal-Bolus and Premixed Insulin Regimens in Hospitalized Patients With Type 2 Diabetes.

Authors:  Virginia Bellido; Lorena Suarez; Maria Galiana Rodriguez; Cecilia Sanchez; Marta Dieguez; Maria Riestra; Florentino Casal; Elias Delgado; Edelmiro Menendez; Guillermo E Umpierrez
Journal:  Diabetes Care       Date:  2015-10-12       Impact factor: 19.112

10.  Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study.

Authors:  Katarzyna Nabrdalik; Hanna Kwiendacz; Tomasz Sawczyn; Andrzej Tomasik; Michał Kukla; Małgorzata Masierek; Janusz Gumprecht
Journal:  Int J Endocrinol       Date:  2018-03-05       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.